Skip to main content

Table 1 Characteristics of PDAC patients at baseline and after the chemotherapy

From: Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy

Stage(s)

Classification

n

Survival (month) (mean ± SD)

CA 19-9 (units/ml) (median (range))

Baseline

After chemotherapy

III

Good-responder

11

23.5 ± 4.9

179.5 (85.7, 371.2)

25.6 (9.7, 148.2)

 

Limited-responder

8

7.3 ± 3.2

447.4 (50.4, 17,089.3)

517.3 (19.8, 1388.5)

IV

Good-responder

15

20.1 ± 8.1

1116.8 (112.3, 5229.2)

250.1 (13.3, 1851.8.4)

 

Limited-responder

18

6.7 ± 3.8

5532.8 (426.0, 64,178.0)

4642.0 (195.7, 88,904.1)

III and IV

Good-responder

26

21.6 ± 7.0

395.9 (67.1, 4451.9)

125.3 (9.0, 795.0)

 

Limited-responder

26

6.9 ± 3.5

3164.5 (80.2, 51,831.1)

1123.9 (26.0, 55,992.8)